

TANDEM DIABETES CARE INC  
Form S-1MEF  
February 09, 2018

As filed with the Securities and Exchange Commission on February 8, 2018

Registration No. 333-

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM S-1**  
**REGISTRATION STATEMENT**  
***UNDER***  
***THE SECURITIES ACT OF 1933***

**Tandem Diabetes Care, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**3841**  
**(Primary Standard Industrial**  
**Classification Code Number)**  
**11075 Roselle Street**

**20-4327508**  
**(I.R.S. Employer**  
**Identification Number)**

**San Diego, California 92121**

**(858) 366-6900**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Kim D. Blickenstaff**

**President and Chief Executive Officer**

**11075 Roselle Street**

**San Diego, California 92121**

**(858) 366-6900**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

*Copies to:*

**Bruce Feuchter, Esq.**

**David B. Berger, Esq.**

**Per B. Chilstrom, Esq.**

**Ryan C. Wilkins, Esq.**

**Executive Vice President, General  
Counsel and Secretary**

**Clifford Chance US LLP**

**Stradling Yocca Carlson & Rauth,  
P.C.**

**Tandem Diabetes Care, Inc.**

**31 West 52nd Street**

**660 Newport Center Drive, Suite  
1600**

**11075 Roselle Street**

**New York, New York 10019**

**Newport Beach, California 92660**

**San Diego, California 92121**

**(212) 878-8000**

**(949) 725-4000**

**(858) 366-6900**

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date of this registration statement.

Edgar Filing: TANDEM DIABETES CARE INC - Form S-1MEF

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. (File No. 333-222553)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.

**CALCULATION OF REGISTRATION FEE**

| <b>Title of each Class of</b>             | <b>Proposed<br/>Maximum<br/>Aggregate</b> | <b>Amount of</b>              |
|---|---|-------------------------------|
| <b>Securities to be Registered</b>        | <b>Offering Price(1)</b>                  | <b>Registration Fee(2)(3)</b> |
| Common Stock, \$0.001 par value per share | \$11,499,908                              | \$1,432                       |

(1) Includes shares of our common stock that the underwriters have an option to purchase.

(2) Calculated pursuant to Rule 457(o) of the Securities Act of 1933, as amended.

(3) We previously registered an aggregate of \$57,500,092 of our common stock on a Registration Statement on Form S-1 (File No. 333-222553), as amended, which was declared effective on February 8, 2018 and for which a filing fee of \$7,159 was previously paid.

**This registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.**

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE**

This Registration Statement on Form S-1 (the **Rule 462(b) Registration Statement**) is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the **Securities Act**), for the purpose of registering an additional \$11,499,908 in shares of the common stock, \$0.001 par value per share (the **Common Stock**), of Tandem Diabetes Care, Inc. (the **Company**). This Rule 462(b) Registration Statement relates to the public offering of the Common Stock of the Company contemplated by the Registration Statement on Form S-1 (File No. 333-222553), which was initially filed with the Securities and Exchange Commission (the **Commission**) on January 16, 2018, as amended by Amendment No. 1 thereto filed on January 29, 2018 and Amendment No. 2 thereto filed on February 8, 2018 (as such may be amended or supplemented from time to time hereafter, the **Registration Statement**). The Registration Statement was declared effective by the Commission on February 8, 2018.

Pursuant to Rule 462(b) under the Securities Act, the contents of the Registration Statement, including the exhibits thereto, are hereby incorporated by reference into this Rule 462(b) Registration Statement.

---

**INDEX OF EXHIBITS**

| Exhibit<br>Number | Exhibit Description  | Incorporated by Reference |          |                         | Exhibit<br>Number | Provided<br>Herewith |
|-------------------|--|---------------------------|----------|-------------------------|-------------------|----------------------|
|                   |  | Form                      | File No. | Date of<br>First Filing |                   |                      |
| 5.1               | <u>Opinion of Stradling Yocca Carlson &amp; Rauth,<br/>P.C.</u>                            |                           |          |                         |                   | X                    |
| 23.1              | <u>Consent of Independent Registered Public<br/>Accounting Firm.</u>                       |                           |          |                         |                   | X                    |
| 23.2              | <u>Consent of Stradling Yocca Carlson &amp; Rauth,<br/>P.C. (included in Exhibit 5.1).</u> |                           |          |                         |                   | X                    |
| 24.1*             | <u>Power of Attorney.</u>  |                           |          |                         |                   |                      |

\* Incorporated by reference to the Registration Statement on Form S-1 (File No. 333-222553), which was initially filed with the Commission on January 16, 2018 and declared effective by the Commission on February 8, 2018.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in San Diego, California on February 8, 2018.

**Tandem Diabetes Care, Inc.**

By: /s/ KIM D. BLICKENSTAFF  
Kim D. Blickenstaff

President and Chief Executive Officer

(Principal Executive Officer)

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

| <b>Signature</b>                               | <b>Title</b>  | <b>Date</b>      |
|--|---|------------------|
| /s/ KIM D. BLICKENSTAFF<br>Kim D. Blickenstaff | President, Chief Executive Officer and Director<br>(Principal Executive Officer)                                | February 8, 2018 |
| /s/ LEIGH A. VOSELLER<br>Leigh A. Vosseller    | Senior Vice President, Chief Financial Officer and<br>Treasurer (Principal Financial and Accounting<br>Officer) | February 8, 2018 |
| *<br>Dick P. Allen                             | Director and Chairman of the Board  | February 8, 2018 |
| *<br>Edward L. Cahill                          | Director  | February 8, 2018 |
| *<br>Fred E. Cohen, M.D., D.Phil, F.A.C.P.     | Director  | February 8, 2018 |
| *<br>Howard E. Greene, Jr.                     | Director  | February 8, 2018 |
| *<br>Douglas A. Roeder                         | Director  | February 8, 2018 |

\*

Director

February 8, 2018

Christopher J. Twomey

\*By: /s/ Kim D. Blickenstaff  
Kim D. Blickenstaff

Attorney-in-Fact